DiaGenic ASA & Ferrer inCode Company Profile
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts. Significant potential in numerous diseases such as breast cancer and Alzheimer's disease has been identified. The company has been granted patents in the U.S. and Europe. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com
News Articles
DiaGenic ASA: Notification of Trade among Primary Insiders
Regulatory News: Reference is made to the stock exchange announcement from DiaGenic ASA ("DiaGenic" or the Company")(OSE:DIAG) on 8 March 2013 regarding the conducted private placement in which th...
DiaGenic ASA: Allotment of Share Options
Regulatory News: According to the resolution by the General Meeting on 23 May 2011 and 14 August 2012, the Board of Directors in DiaGenic ASA (OSE:DIAG) today allotted options to DiaGenic employee...
DiaGenic ASA: Proposal from the Nomination Committee
Regulatory News: DiaGenic ASA (OSE:DIAG): Please see the following link for the proposal from the nomination committee in DiaGenic ASA to the Company's General Meeting on 23 May 2013: http://mb.ci...
DiaGenic ASA: Annual Report for 2012
Regulatory News: Please find enclosed DiaGenic's Annual Report for 2012. http://mb.cision.com/Public/115/9390322/a0210d4d4a26b474.pdf The report is also available on DiaGenic's webpage: www.diagen...
DiaGenic ASA: Disclosure of Voting Rights
Regulatory News: Henrik Lund, chairman of DiaGenic ASA (OSE:DIAG), has as per 25 March 2013 received proxies to vote (without instructions) for a total of 1,515,875 shares at the company's extraor...
DiaGenic ASA: Increase in share capital
Regulatory News: Reference is made to the stock exchange announcement from DiaGenic ASA (the "Company")(OSE:DIAG) dated 29 April 2013 regarding the result in the subsequent repair offering. The sh...
DiaGenic ASA: DiaGenic - Raises NOK 30 Million in a Private Placement
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEAS...
DiaGenic ASA: Final Result in the Subsequent Repair Offering
Regulatory News: DiaGenic: (OSE:DIAG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY O...
Drugs and Medications
None
PubMed Articles
New role for Spinophilin in tumor suppression.
Comment on: Ferrer I, et al. Cell Cycle 2011; 10:2751-62.
Reply to Ferrer et al.: propensity scores in intensive care literature.
Synergy between quantum dots and 1,10-phenanthroline-copper(ii) complex towards cleaving DNA.
We have found that the DNA cleaving activity of quantum dots and 1,10-phenanthroline-Cu(ii) complex is significantly enhanced when they are combined.
Cover image, volume 33, issue 24.
A theoretical study of the hydrolysis of a b-lactam antibiotic, cefotaxime (CEF), in gas phase with semi-empirical and density functional theory (DFT) methods, and in aqueous solution by means of hybr...
Clinical Trials
None
Companies
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for...
DiaGenic ASA benefits from strong shareholders, a qualified staff and Board of Directors representing a wide range of experience. The company currently has nine employees and is located at Helsfyr in...
Ferrer Grupo offers products of a high scientific standard, according to client needs, together with health training programmes which provide up-to-date information on the constant improvements in the...
Ferrer Freeman & Company, LLC, is a private equity firm located in Greenwich, CT focuses exclusively on growth capital investments in the healthcare industry. Since its founding i...
More Information about "DiaGenic ASA & Ferrer inCode" on BioPortfolio
We have published hundreds of DiaGenic ASA & Ferrer inCode news stories on BioPortfolio along with dozens of DiaGenic ASA & Ferrer inCode Clinical Trials and PubMed Articles about DiaGenic ASA & Ferrer inCode for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of DiaGenic ASA & Ferrer inCode Companies in our database. You can also find out about relevant DiaGenic ASA & Ferrer inCode Drugs and Medications on this site too.
